Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure
Sodium glucose cotransporter-2 (SGLT-2) inhibitors have been widespread in patients with heart failure; however, there is little information regarding its feasibility and safety among patients after the Fontan procedure. We presented five adults after the Fontan procedure who were treated with SGLT-...
Saved in:
Main Authors: | Jun Muneuchi, Yuichiro Sugitani, Masaru Kobayashi, Hiroki Ezaki, Hiromu Yamada, Mamie Watanabe |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Case Reports in Cardiology |
Online Access: | http://dx.doi.org/10.1155/2022/5243594 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors
by: Riber Fabián Donoso Noroña, et al.
Published: (2024-09-01) -
Sodium‐Glucose Cotransporter 2 Inhibitors for Mesenchymal–Epithelial Transition Inhibitor‐Induced Edema
by: Takuya Oyakawa, et al.
Published: (2025-01-01) -
Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01) -
Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
by: Yuri Sakai Ishizaki, et al.
Published: (2024-11-01) -
Unmasking of normocalcemic primary hyperparathyroidism after sodium-glucose cotransporter-2 inhibitor initiation
by: Christodoulos Dolapsakis, et al.
Published: (2025-01-01)